Meat Protein delivers outstanding top-line growth
of 13.4%, Adjusted EBITDA Margin of 13.0% and Adjusted EBITDA
dollar growth of 21.8%; Reassessing Plant Protein
investment
TSX:
MFI
www.mapleleaffoods.com
MISSISSAUGA, ON, Nov. 4,
2021 /PRNewswire/ - Maple Leaf Foods Inc. ("Maple Leaf Foods" or
the "Company") (TSX: MFI) today reported its financial results for
the third quarter ended September 30, 2021.
"Our meat protein business delivered exceptional results in the
third quarter," said Michael H.
McCain, President and CEO of Maple Leaf Foods. "Our revenue
grew by over 13% and our Adjusted EBITDA grew by 22%, driven by a
90 bps improvement in margin to 13.0%, the result of outstanding
execution of our strategies to become the most sustainable protein
company on earth. I am grateful for the tireless commitment of our
teams who are consistently delivering, and confident in achieving
our near-term targets.
"We are seeing a marked slowdown in the plant-based protein
category performance which may suggest systemic change in the
extremely high growth rates expected by the industry," continued
Mr. McCain. "While our overall focus to create long-term value for
all stakeholders remains unchanged, and investments to date have
been well calculated, well executed and have delivered underlying
value, we have always been prepared to re-examine that investment
thesis if circumstances change. Given current category performance,
such a review is underway which will either affirm or adjust our
strategies and investment thesis going forward."
Third Quarter 2021 Highlights
- Total Company sales grew 12.4% to $1,188.6 million, with an Adjusted Earnings
Before Interest, Taxes, Depreciation and Amortization
("EBITDA")(i) Margin of 9.7%, up from 7.8% last
year.
- Meat Protein Group sales grew 13.4% to $1,150.3 million, driven by higher fresh pork and
poultry prices and a favourable mix-shift towards branded products
and sustainable meats.
- Meat Protein Group Adjusted EBITDA grew by 21.8% to
$149.3 million which is a 90 bps
increase in Adjusted EBITDA Margin to 13.0% (13.2% excluding
start-up costs related to near completion Construction
Capital(i)), compared to 12.1% last year.
- Plant Protein Group sales have declined by 6.6% (decline of
1.2% excluding the impact of foreign exchange) due to declining
retail sales within the category, offset by growth in foodservice
volumes.
- Net earnings were $44.5 million,
compared to $66.0 million last year
primarily due to non-cash fair value changes in biological assets
and derivative contracts.
- Capital expenditures were $152.9
million and consisted predominantly of Construction Capital
of $123.3 million, the majority of
which was related to the ongoing construction of the London, Ontario poultry facility and the
expansion of the previously announced Bacon Centre of Excellence in
Winnipeg, Manitoba.
- Balance sheet remained strong with Net
Debt(i) of $1,089.5
million and undrawn committed credit of over $800 million.
- 2021 Outlook: Meat Protein Group targets unchanged –
mid-to-high single digit sales growth and Adjusted EBITDA Margin
expansion. Driven largely by the lower than expected growth in the
plant protein category, the Company does not expect to meet its
Plant Protein Group sales growth target for the second half of 2021
and will not likely have a further view on near term sales growth
targets until it has completed its reassessment of the
category.
(i)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
Financial Highlights
|
|
As at or for
the
|
Measure(i)
(Unaudited)
|
Three months ended
September 30,
|
nine months ended
September 30,
|
2021
|
2020
|
Change
|
2021
|
2020
|
Change
|
Sales
|
$
|
1,188.6
|
$
|
1,057.2
|
12.4%
|
$
|
3,400.6
|
$
|
3,174.5
|
7.1%
|
Net Earnings
|
$
|
44.5
|
$
|
66.0
|
(32.6)%
|
$
|
100.9
|
$
|
87.9
|
14.8%
|
Basic Earnings per
Share
|
$
|
0.36
|
$
|
0.54
|
(33.3)%
|
$
|
0.82
|
$
|
0.72
|
13.9%
|
Adjusted Operating
Earnings(ii)
|
$
|
68.0
|
$
|
36.9
|
84.3%
|
$
|
174.7
|
$
|
148.7
|
17.5%
|
Adjusted Earnings per
Share(ii)
|
$
|
0.36
|
$
|
0.17
|
111.8%
|
$
|
0.90
|
$
|
0.73
|
23.3%
|
Adjusted EBITDA - Meat
Protein Group(ii)
|
$
|
149.3
|
$
|
122.6
|
21.8%
|
$
|
402.3
|
$
|
371.9
|
8.2%
|
Sales - Plant Protein
Group
|
$
|
48.0
|
$
|
51.4
|
(6.6)%
|
$
|
138.6
|
$
|
158.3
|
(12.4)%
|
Free Cash
Flow(ii)
|
$
|
(5.5)
|
$
|
57.8
|
(109.5)%
|
$
|
(336.6)
|
$
|
(21.8)
|
(1,444.0)%
|
Construction
Capital(ii)
|
|
|
|
|
$
|
844.1
|
$
|
303.0
|
178.6%
|
Net
Debt(ii)
|
|
|
|
|
$
|
(1,089.5)
|
$
|
(534.9)
|
103.7%
|
(i)
|
All financial
measures in millions of dollars except Basic and Adjusted Earnings
per Share.
|
(ii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
Sales for the third quarter of 2021 were $1,188.6 million compared to $1,057.2 million last year, an increase of 12.4%,
driven by higher sales in the Meat Protein Group, partially offset
by lower sales in the Plant Protein Group. For more details on
sales performance by operating segment, please refer to the section
titled Operating Review.
Year-to-date sales for 2021 were $3,400.6
million compared to $3,174.5
million last year, an increase of 7.1%, due to similar
factors as noted above.
Net earnings for the third quarter of 2021 were $44.5 million ($0.36 per basic share) compared to $66.0 million ($0.54 per basic share) last year. Strong
commercial performance and effective commodity hedges were more
than offset by a reduction in net gains from non-cash fair value
changes in biological assets and derivative contracts (2021: net
loss of $0.1 million; 2020: net gain
of $64.0 million), both of which are
excluded in the calculation of Adjusted Operating Earnings.
Year-to-date net earnings for 2021 were $100.9 million ($0.82 per basic share) compared to $87.9 million ($0.72 per basic share) last year. Strong
commercial performance and effective commodity hedges were more
than offset by an increase in non-cash fair value changes in
biological assets and derivative contracts (2021: net gain of
$5.0 million; 2020: net loss of
$10.2 million), both of which are
excluded in the calculation of Adjusted Operating Earnings.
Adjusted Operating Earnings for the third quarter of 2021 were
$68.0 million compared to
$36.9 million last year, and Adjusted
Earnings per Share for the third quarter of 2021 were $0.36 compared to $0.17 last year due to similar factors as noted
above.
Year-to-date Adjusted Operating Earnings for 2021 were
$174.7 million compared to
$148.7 million last year, and
Adjusted Earnings per Share for 2021 were $0.90 compared to $0.73 last year due to similar factors as noted
above.
For further discussion on key metrics and a discussion of
results by operating segment, refer to the section titled Operating
Review.
Note: Several items are excluded from the discussions of
underlying earnings performance as they are not representative of
ongoing operational activities. Refer to the section entitled
Non-IFRS Financial Measures at the end of this news release for a
description and reconciliation of all non-IFRS financial
measures.
Response to COVID-19
As an essential service, Maple Leaf Foods is focused on
protecting the health and well-being of its people, maintaining
business continuity, and broadening its social outreach. To manage
through this unprecedented environment, the Company has taken a
number of measures in its business and operating practices that
include heightened safety policies and procedures, and close
communication and collaboration with public health authorities
including on-site vaccination clinics. The measures enacted to
protect the health and safety of employees have increased the
Company's cost structure due to higher labour, personal protective
equipment, sanitation and other expenses associated with the
pandemic. Continuing COVID-19 structural costs have been
incorporated in the Company's 2021 operating plan.
Overall, the Company believes its proactive and comprehensive
efforts have, and should continue to mitigate adverse operational
impacts. As the COVID-19 situation evolves, Maple Leaf Foods will
continue to adapt and adopt best practices that prioritize the
health and safety of its employees and the stability of the food
supply. As part of Maple Leaf Foods' broader social responsibility
since the pandemic began, the Company has provided extensive
support to front-line staff, emergency food relief efforts and
health care providers.
COVID-19 continues to have an impact on the global economy,
leading to increased inflation, labour shortages and disruptions in
the global supply chain. To date, the Company's leading brands,
revenue management capabilities and robust supply chain have
enabled it to manage these impacts. Maple Leaf Foods continues to
monitor the ongoing environment and believes it is well positioned
to face these headwinds.
Operating Review
The Company has two reportable segments. These segments offer
different products, with separate organizational structures,
brands, financial, and marketing strategies. The Company's chief
operating decision makers regularly review internal reports for
these businesses: performance of the Meat Protein Group is based on
revenue growth, Adjusted Operating Earnings and Adjusted EBITDA,
while the performance of the Plant Protein Group is based
predominantly on revenue growth rates, gross margin optimization
and controlling SG&A investment levels, which generate high
revenue growth rates.
The following table summarizes the Company's sales, gross
profit, SG&A expenses, Adjusted Operating Earnings, Adjusted
EBITDA, and Adjusted EBITDA Margin by operating segment for the
three months ended September 30, 2021 and September 30,
2020.
|
Three months ended
September 30, 2021
|
Three months ended
September 30, 2020
|
($
millions)(i) (Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Sales
|
$
|
1,150.3
|
48.0
|
(9.7)
|
$
|
1,188.6
|
$
|
1,014.4
|
51.4
|
(8.6)
|
$
|
1,057.2
|
Gross
profit
|
$
|
191.5
|
(3.3)
|
(0.1)
|
$
|
188.2
|
$
|
160.6
|
3.4
|
64.1
|
$
|
228.1
|
Selling, general and
administrative
expenses
|
$
|
85.9
|
34.4
|
—
|
$
|
120.3
|
$
|
80.7
|
46.5
|
—
|
$
|
127.2
|
Adjusted Operating
Earnings(iii)
|
$
|
105.6
|
(37.7)
|
—
|
$
|
68.0
|
$
|
80.0
|
(43.1)
|
—
|
$
|
36.9
|
Adjusted
EBITDA(iii)
|
$
|
149.3
|
(33.9)
|
—
|
$
|
115.4
|
$
|
122.6
|
(39.6)
|
(0.5)
|
$
|
82.6
|
Adjusted EBITDA
Margin(iii)
|
13.0
%
|
(70.8)%
|
n/a
|
9.7%
|
12.1%
|
(77.0)%
|
n/a
|
7.8 %
|
|
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, changes in the fair value of biological assets and
derivatives, and non-allocated costs which are comprised of
expenses not separately identifiable to reportable segments and are
not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
The following table summarizes the Company's sales, gross
profit, SG&A expenses, Adjusted Operating Earnings, Adjusted
EBITDA, and Adjusted EBITDA Margin by operating segment for the
nine months ended September 30, 2021 and September 30,
2020.
|
Nine months ended
September 30, 2021
|
Nine months ended
September 30, 2020
|
($
millions)(i) (Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Sales
|
$
|
3,281.5
|
138.6
|
(19.6)
|
$
|
3,400.6
|
$
|
3,036.2
|
158.3
|
(20.0)
|
$
|
3,174.5
|
Gross
profit
|
$
|
524.6
|
(2.9)
|
(5.0)
|
$
|
516.8
|
$
|
494.5
|
18.0
|
10.2
|
$
|
522.8
|
Selling, general and
administrative
expenses
|
$
|
254.1
|
93.0
|
—
|
$
|
347.1
|
$
|
252.4
|
111.5
|
—
|
$
|
363.9
|
Adjusted Operating
Earnings(iii)
|
$
|
270.5
|
(95.8)
|
—
|
$
|
174.7
|
$
|
242.1
|
(93.5)
|
—
|
$
|
148.7
|
Adjusted
EBITDA(iii)
|
$
|
402.3
|
(84.8)
|
—
|
$
|
317.5
|
$
|
371.9
|
(82.7)
|
(0.5)
|
$
|
288.8
|
Adjusted EBITDA
Margin(iii)
|
|
12.3
%
|
(61.2)%
|
n/a
|
|
9.3
%
|
|
12.2 %
|
|
(52.2)%
|
n/a
|
|
9.1 %
|
|
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, changes in the fair value of biological assets and
derivatives, and non-allocated costs which are comprised of
expenses not separately identifiable to reportable segments and are
not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
Refer to the section
titled Non-IFRS Financial Measures in this news
release.
|
Meat Protein Group
The Meat Protein Group is comprised of prepared meats,
ready-to-cook and ready-to-serve meals, value-added fresh pork and
poultry products that are sold to retail, foodservice and
industrial channels, and agricultural operations in pork and
poultry. The Meat Protein Group includes leading brands such as
Maple Leaf®, Maple Leaf Prime®, Schneiders®, Mina®, Greenfield
Natural Meat Co.® and many leading regional brands.
Sales for the third quarter of 2021 increased 13.4% to
$1,150.3 million compared to
$1,014.4 million last year. Growth in
sales is driven by pricing action implemented in the third quarter
of 2021 to mitigate meat inflation, growth in fresh volumes from an
increase in hogs and birds processed, and a favourable mix-shift
towards sustainable meats and branded products. These factors more
than offset an unfavourable impact from lower prepared meats
volumes, foreign exchange, and lower sales to China.
Year-to-date sales for 2021 increased 8.1% to $3,281.5 million compared to $3,036.2 million last year. Sales growth was
driven by pricing actions taken in the fourth quarter of 2020 and
the third quarter of 2021 to mitigate inflation and structural cost
increases, favourable mix-shift towards sustainable meats and
branded products, and growth in fresh volumes from an increase in
hogs and birds processed. These factors more than offset an
unfavourable impact from foreign exchange, lower prepared meats
volumes, and lower sales to China.
Gross profit for the third quarter of 2021 was $191.5 million (gross margin of 16.6%) compared
to $160.6 million (gross margin of
15.8%) last year. Gross profit benefited from strong commercial
performance and effective commodity hedges including a favourable
product and channel mix attributed to expansion of sustainable
meats and other branded products, more than offsetting cost
pressure in the supply chain primarily due to labour challenges and
$2.0 million in start-up costs
associated with Construction Capital projects. The third quarter of
2020 was also impacted by heightened operating costs in response to
COVID-19 to safeguard the Company's employees.
Year-to-date gross profit for 2021 was $524.6 million (gross margin of 16.0%) compared
to $494.5 million (gross margin of
16.3%) last year. This increase is attributable to strong
performance in branded products and value added sustainable meats,
and effective hedges more than offsetting lower profits in
China, higher structural costs and
$4.1 million in start-up costs
associated with Construction Capital projects. Gross profit in the
first three quarters of 2020 was also impacted by significant
operational and one-off costs in response to COVID-19.
SG&A expenses for the third quarter of 2021 were
$85.9 million compared to
$80.7 million last year. The increase
in SG&A expenses was driven by the timing of advertising and
promotional expenses and a gradual normalization of discretionary
spending as COVID-19 restrictions relaxed.
Year-to-date SG&A expenses for 2021 were $254.1 million compared to $252.4 million last year. The increase in
SG&A was driven by timing of advertising and promotional spend,
partially offset by the lapping of donations made in March 2020 to support front-line health care
workers at the outset of the COVID-19 pandemic.
Adjusted Operating Earnings for the third quarter of 2021 were
$105.6 million compared to
$80.0 million last year, consistent
with factors noted above.
Year-to-date Adjusted Operating Earnings for 2021 were
$270.5 million compared to
$242.1 million last year, consistent
with factors noted above.
Adjusted EBITDA for the third quarter of 2021 were $149.3 million compared to $122.6 million last year, driven by factors
consistent with those noted above. Adjusted EBITDA Margin for the
third quarter was 13.0% compared to 12.1% last year, also driven by
factors consistent with those noted above.
Year-to-date Adjusted EBITDA for 2021 were $402.3 million compared to $371.9 million last year, driven by factors
consistent with those noted above. Year-to-date Adjusted EBITDA
Margin for 2021 was 12.3% compared to 12.2% last year, also driven
by factors consistent with those noted above.
Plant Protein Group
The Plant Protein Group is comprised of refrigerated plant
protein products, premium grain-based protein, and vegan cheese
products sold to retail, foodservice and industrial channels. The
Plant Protein Group includes the leading brands Lightlife® and
Field Roast™.
Sales for the third quarter of 2021 decreased 6.6% to
$48.0 million compared to
$51.4 million last year. Excluding
the impact of foreign exchange, sales decreased 1.2%, driven by
lower volumes in fresh and core retail products. This more than
offset growth in foodservice volumes and pricing action implemented
at the end of the third quarter of 2020 to mitigate inflation and
structural cost increases.
Year-to-date sales for 2021 decreased 12.4% to $138.6 million compared to $158.3 million last year. Excluding the impact of
foreign exchange, sales decreased 5.0%, driven by lower volumes in
retail products. This more than offset growth in foodservice
volumes and pricing action implemented at the end of the third
quarter of 2020 to mitigate inflation and structural cost
increases.
Gross profit for the third quarter of 2021 was a loss of
$3.3 million (gross margin loss of
6.8%) compared to income of $3.4
million (gross margin of 6.6%) last year. The decrease in
gross profit was attributed to lower sales volumes and strategic
investments in capacity to build for anticipated demand which has
resulted in increased overhead and transitory costs, as well as
inflationary pressure on labour and other input costs. The third
quarter of 2020 was also impacted by heightened operating costs in
response to COVID-19 to safeguard the Company's employees.
Year-to-date gross profit for 2021 was a loss of $2.9 million (gross margin loss of 2.1%) compared
to income of $18.0 million (gross
margin of 11.4%) last year. The decrease in gross profit was
primarily attributed to lower sales volumes and strategic
investments in capacity to build for anticipated demand which has
resulted in increased overhead and transitory costs, as well as
inflationary pressure on labour and other input costs. Gross profit
in the first three quarters of 2020 was also impacted by
significant operational and one-off costs in response to
COVID-19.
SG&A expenses for the third quarter of 2021 were
$34.4 million (71.7% of sales)
compared to $46.5 million (90.5% of
sales) last year. The decrease in SG&A expenses was primarily
driven by the timing of advertising and promotional expenses.
Year-to-date SG&A expenses for 2021 were $93.0 million (67.0% of sales) compared to
$111.5 million (70.4% of sales) last
year. The decrease in SG&A was driven by the timing of
advertising and promotional expenses.
Adjusted Operating Earnings for the third quarter of 2021 were a
loss of $37.7 million compared to a
loss of $43.1 million last year. The
increase in Adjusted Operating Earnings is consistent with the
factors noted above.
Year-to-date Adjusted Operating Earnings for 2021 were a loss of
$95.8 million compared to a loss of
$93.5 million last year. The decrease
in Adjusted Operating Earnings is consistent with the factors noted
above.
Other Matters
On November 3, 2021, the Board of
Directors approved a quarterly dividend of $0.18 per share, $0.72 per share on an annual basis, payable
December 31, 2021 to shareholders of
record at the close of business December 8,
2021. Unless indicated otherwise by the Company at or before
the time the dividend is paid, the dividend will be considered an
eligible dividend for the purposes of the "Enhanced Dividend Tax
Credit System".
Conference Call
A conference call will be held at 8:00 a.m. ET on
November 4, 2021, to review Maple Leaf Foods' third quarter
financial results. To participate in the call, please dial
416-764-8650 or 1-888-664-6383. For those unable to participate,
playback will be made available an hour after the event at
416-764-8677 or 1-888-390-0541 (Passcode: 592170#).
A webcast of the third quarter conference call will also be
available at:
https://www.mapleleaffoods.com
The Company's full unaudited condensed consolidated interim
financial statements ("Consolidated Interim Financial Statements")
and related Management's Discussion and Analysis are available on
the Company's website.
An investor presentation related to the Company's third quarter
financial results is available at www.mapleleaffoods.com and
can be found under Presentations and Webcasts on the
Investors page.
2021 Outlook
Throughout the COVID-19 pandemic, Maple Leaf Foods has remained
focused on protecting its employees and ensuring continuity of its
supply chain. As a result, the current environment does increase
certain operating costs and potential for short-term processing
disruptions to protect the health and safety of plant personnel.
Continuing COVID-19 structural costs have been incorporated in the
Company's 2021 operating plan.
Based on year-to-date performance and the Company's outlook for
the balance of the year, Maple Leaf Foods expects to achieve the
following in 2021:
Meat Protein Group - Driving Profitable Growth
- Mid-to-high single digit sales growth on a 52-week comparable
basis, driven by continued momentum in sustainable meats,
leveraging brand renovation, and growth into the U.S. market.
- Adjusted EBITDA margin expansion, progressing towards the 2022
target of 14% - 16%, driven by mix-shift benefits in prepared meats
resulting from growth in sustainable meats and brand renovation, as
well as operational efficiencies, while assuming pork complex
conditions in-line with the 5-year average.
Plant Protein Group - Investing for Growth
- Gross margin is expected to be volatile in the near-term, as
benefits from structural improvements in the supply chain may be
impacted by investment opportunities to drive sales growth in a
rapidly evolving market, as well as ongoing effects of
COVID-19.
- SG&A expenses broadly in-line with 2020 levels, excluding
any impact from fluctuations in foreign exchange, while declining
as a percentage of sales as the Company leverages investments in
advertising, promotion and marketing to elevate the Lightlife® and
Field Roast™ brand renovations, drive innovation and build scale in
the business.
- Driven largely by the lower than expected growth in the plant
protein category, the Company does not expect to meet its sales
growth target for the second half of 2021 and will not likely have
a further view on near term sales growth targets until it has
completed its reassessment of the category.
Capital
- The Company's capital expenditure estimate for the full year of
2021 remains unchanged and at the high end of the range of
$550 million to $650 million, with approximately 75% to be
comprised of Construction Capital. A significant portion of the
Construction Capital is related to the London, Ontario poultry facility, the plant
protein facility in Indianapolis,
Indiana and the expansion of the Bacon Centre of Excellence
in Winnipeg, Manitoba.
Factors that could have an impact on the business, which cannot
be estimated or controlled due to the COVID-19 pandemic,
include:
- Volatility in the pork and poultry commodity and foreign
exchange markets.
- Inflationary cost pressures.
- Disruptions in the global supply chain.
- Availability of labour.
- The balance between retail and foodservice demand.
- Potential future production disruptions or shutdowns.
- The duration of government measures, including social
distancing.
In addition to financial and operational priorities, Maple Leaf
Foods believes that shared value and operating its business for the
benefit of all stakeholders is crucial. The Company's guiding
pillars to be the "Most Sustainable Protein Company on Earth"
include Better Food, Better Care, Better Communities, Better Planet
and are core to how Maple Leaf Foods conducts itself. To that end,
the Company's priorities include:
- Better Food - leading the real food movement and
transitioning key brands to 100% "raised without antibiotics".
- Better Care - further advancement of animal care,
including progress towards transitioning all sows under management
to open housing systems by 2022.
- Better Communities - investing approximately 1% of
pre-tax profit to advance sustainable food security.
- Better Planet - continuing to amplify its commitment to
carbon neutrality, while focusing on eliminating waste in any
resources it consumes, including food, energy, water, packaging,
and time.
Non-IFRS Financial Measures
The Company uses the following non-IFRS measures: Adjusted
Operating Earnings, Adjusted Earnings per Share, Adjusted EBITDA,
Adjusted EBITDA Margin, Construction Capital, Net Debt, Free Cash
Flow and Return on Net Assets. Management believes that these
non-IFRS measures provide useful information to investors in
measuring the financial performance of the Company for the reasons
outlined below. These measures do not have a standardized meaning
prescribed by IFRS and therefore they may not be comparable to
similarly titled measures presented by other publicly traded
companies and should not be construed as an alternative to other
financial measures determined in accordance with IFRS.
Adjusted Operating Earnings, Adjusted EBITDA and Adjusted
EBITDA Margin
Adjusted Operating Earnings, Adjusted EBITDA and Adjusted EBITDA
Margin are non-IFRS measures used by Management to evaluate
financial operating results. Adjusted Operating Earnings is defined
as earnings before income taxes and interest expense adjusted for
items that are not considered representative of ongoing operational
activities of the business and items where the economic impact of
the transactions will be reflected in earnings in future periods
when the underlying asset is sold or transferred. Adjusted EBITDA
is defined as Adjusted Operating Earnings plus depreciation and
intangible asset amortization, adjusted for items included in other
expense that are considered representative of ongoing operational
activities of the business. Adjusted EBITDA Margin is calculated as
Adjusted EBITDA divided by sales.
The tables below provide a reconciliation of earnings (loss)
before income taxes as reported under IFRS in the Consolidated
Interim Financial Statements to Adjusted Operating Earnings and
Adjusted EBITDA for the three and nine months ended
September 30, 2021 as indicated below. Management believes
that these non-IFRS measures are useful in assessing the
performance of the Company's ongoing operations and its ability to
generate cash flows to fund its cash requirements, including the
Company's capital investment program.
|
Three months ended
September 30, 2021
|
Three months ended
September 30, 2020
|
($
millions)(i) (Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Earnings (loss)
before income taxes
|
$
|
105.3
|
(37.9)
|
(5.2)
|
$
|
62.3
|
$
|
79.8
|
(43.2)
|
53.7
|
$
|
90.4
|
Interest expense and
other financing costs
|
—
|
—
|
5.7
|
5.7
|
—
|
—
|
7.5
|
7.5
|
Other (income)
expense
|
(0.6)
|
0.2
|
(0.6)
|
(1.0)
|
(1.6)
|
0.0
|
2.9
|
1.4
|
Restructuring and other
related costs
|
0.8
|
—
|
—
|
0.8
|
1.7
|
—
|
—
|
1.7
|
Earnings (loss) from
operations
|
$
|
105.6
|
(37.7)
|
(0.1)
|
$
|
67.9
|
$
|
80.0
|
(43.1)
|
64.1
|
$
|
100.9
|
Change in fair value of
biological assets
|
—
|
—
|
(6.6)
|
(6.6)
|
—
|
—
|
(40.2)
|
(40.2)
|
Unrealized loss (gain)
on derivative contracts
|
—
|
—
|
6.7
|
6.7
|
—
|
—
|
(23.9)
|
(23.9)
|
Adjusted Operating
Earnings
|
$
|
105.6
|
(37.7)
|
—
|
$
|
68.0
|
$
|
80.0
|
(43.1)
|
—
|
$
|
36.9
|
Depreciation and
amortization
|
43.1
|
3.9
|
—
|
47.0
|
44.1
|
3.6
|
—
|
47.7
|
Items included in other
income (expense)
representative of ongoing
operations(iii)
|
0.6
|
(0.2)
|
—
|
0.4
|
(1.5)
|
0.0
|
(0.5)
|
(2.0)
|
Adjusted
EBITDA
|
$
|
149.3
|
(33.9)
|
—
|
$
|
115.4
|
$
|
122.6
|
(39.6)
|
(0.5)
|
$
|
82.6
|
Adjusted EBITDA
Margin
|
|
13.0
%
|
(70.8)%
|
n/a
|
|
9.7
%
|
|
12.1 %
|
(77.0)%
|
n/a
|
|
7.8 %
|
|
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are comprised of income
and expenses not separately identifiable to reportable segments and
are not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
2021 primarily
includes legal settlements, gains and losses on the sale of
long-term assets, and other miscellaneous expenses. 2020 primarily
includes gains and losses on sale of long-term assets and gains and
losses on equity investments.
|
|
Nine months ended
September 30, 2021
|
Nine months ended
September 30, 2020
|
($
millions)(i) (Unaudited)
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Meat
Protein
Group
|
Plant
Protein
Group
|
Non-
Allocated(ii)
|
Total
|
Earnings (loss)
before income taxes
|
$
|
268.3
|
(96.2)
|
(29.6)
|
$
|
142.4
|
$
|
240.8
|
(93.5)
|
(22.8)
|
$
|
124.5
|
Interest expense and
other financing costs
|
—
|
—
|
16.4
|
16.4
|
—
|
—
|
23.4
|
23.4
|
Other (income)
expense
|
(1.4)
|
0.4
|
8.3
|
7.2
|
(1.8)
|
0.1
|
9.6
|
7.9
|
Restructuring and other
related costs
|
3.7
|
—
|
—
|
3.7
|
3.1
|
—
|
—
|
3.1
|
Earnings (loss) from
operations
|
$
|
270.5
|
(95.8)
|
(5.0)
|
$
|
169.7
|
$
|
242.1
|
(93.5)
|
10.2
|
$
|
158.9
|
Change in fair value of
biological assets
|
—
|
—
|
6.8
|
6.8
|
—
|
—
|
1.2
|
1.2
|
Unrealized gain on
derivative contracts
|
—
|
—
|
(1.8)
|
(1.8)
|
—
|
—
|
(11.4)
|
(11.4)
|
Adjusted Operating
Earnings
|
$
|
270.5
|
(95.8)
|
—
|
$
|
174.7
|
$
|
242.1
|
(93.5)
|
—
|
$
|
148.7
|
Depreciation and
amortization
|
134.4
|
11.3
|
—
|
145.7
|
131.1
|
10.9
|
—
|
141.9
|
Items included in other
income (expense)
representative of ongoing
operations(iii)
|
(2.6)
|
(0.4)
|
—
|
(2.9)
|
(1.3)
|
(0.1)
|
(0.5)
|
(1.8)
|
Adjusted
EBITDA
|
$
|
402.3
|
(84.8)
|
—
|
$
|
317.5
|
$
|
371.9
|
(82.7)
|
(0.5)
|
$
|
288.8
|
Adjusted EBITDA
Margin
|
|
12.3
%
|
(61.2)%
|
n/a
|
|
9.3
%
|
|
12.2 %
|
(52.2)%
|
n/a
|
|
9.1 %
|
|
|
(i)
|
Totals may not add
due to rounding.
|
(ii)
|
Non-allocated
includes eliminations of inter-segment sales and associated cost of
goods sold, and non-allocated costs which are comprised of income
and expenses not separately identifiable to reportable segments and
are not part of the measures used by the Company when assessing a
segment's operating results.
|
(iii)
|
2021 primarily
includes legal settlements, gains and losses on the sale of
long-term assets, and other miscellaneous expenses. 2020 primarily
includes insurance settlements, gains and losses on sale of
long-term assets and gains and losses on equity
investments.
|
Adjusted Earnings per Share
Adjusted Earnings per Share, a non-IFRS measure, is used by
Management to evaluate financial operating results. It is defined
as basic earnings per share and is adjusted on the same basis as
Adjusted Operating Earnings. The table below provides a
reconciliation of basic earnings per share as reported under IFRS
in the Consolidated Interim Financial Statements to Adjusted
Earnings per Share for the three and nine months ended September 30, as indicated below. Management
believes this basis is the most appropriate on which to evaluate
financial results as they are representative of the ongoing
operations of the Company.
($ per
share)
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
(Unaudited)
|
|
2021
|
|
2020
|
|
2021
|
|
2020
|
Basic earnings per
share
|
$
|
0.36
|
$
|
0.54
|
$
|
0.82
|
$
|
0.72
|
Restructuring and other
related costs(i)
|
0.01
|
0.01
|
0.02
|
0.02
|
Items included in other
expense not considered
representative of ongoing
operations(ii)
|
—
|
—
|
0.03
|
0.05
|
Change in fair value of
biological assets
|
(0.04)
|
(0.24)
|
0.04
|
0.01
|
Change in unrealized
fair value on derivatives
|
0.04
|
(0.14)
|
(0.01)
|
(0.07)
|
Adjusted Earnings
per Share(iii)
|
$
|
0.36
|
$
|
0.17
|
$
|
0.90
|
$
|
0.73
|
|
|
(i)
|
Includes per share
impact of restructuring and other related costs, net of
tax.
|
(ii)
|
Primarily includes
legal fees and provisions and transaction related costs, net of
tax.
|
(iii)
|
Totals may not add
due to rounding.
|
Construction Capital
Construction Capital, a non-IFRS measure, is used by Management
to evaluate the amount of capital resources invested in specific
strategic development projects that are not yet operational. It is
defined as investments and related financing charges in projects
over $50.0 million that are related
to longer-term strategic initiatives, with no returns expected for
at least 12 months from commencement of construction and the asset
will be re-categorized from Construction Capital once operational.
Current strategic initiatives primarily include investments in the
London, Ontario poultry production
facility, the expansion of the Bacon Centre of Excellence in
Winnipeg, Manitoba, investments in
plant protein capacity at the Walker Drive facility in Brampton, Ontario, and the plant protein
production facilities in Indiana.
The following table is a summary of Construction Capital activity
and debt financing for the periods indicated below.
($
thousands)
(Unaudited)
|
2021
|
2020
|
Total property,
plant, and equipment and intangibles at January 1
|
$
|
2,062,683
|
$
|
1,739,195
|
Other capital and
intangible assets at January 1(i)
|
1,622,094
|
1,632,365
|
Construction Capital
at January 1
|
$
|
440,589
|
$
|
106,830
|
Additions(ii)
|
152,342
|
57,797
|
Construction Capital
at March 31
|
$
|
592,931
|
$
|
164,627
|
Additions(ii)
|
127,822
|
64,357
|
Construction Capital
at June 30
|
$
|
720,753
|
$
|
228,984
|
Additions(ii)
|
123,321
|
74,036
|
Construction Capital
at September 30(iii)
|
$
|
844,074
|
$
|
303,020
|
Other capital and
intangible assets at September 30(i)
|
1,640,047
|
1,625,220
|
Total property,
plant, and equipment and Intangibles at September 30
|
$
|
2,484,121
|
$
|
1,928,240
|
|
|
|
Construction Capital
debt financing(iv)
|
$
|
821,110
|
$
|
296,980
|
|
|
(i)
|
Other capital and
intangible assets consists of property and equipment and
intangibles that do not meet the definition of Construction
Capital.
|
(ii)
|
Certain comparatives
figures have been restated to conform with current year
presentation.
|
(iii)
|
As at
September 30, 2021, the net book value of construction capital
includes $3.2 million related to intangible assets
(September 30, 2020: $0.6 million; December 31, 2020:
$1.2 million).
|
(iv)
|
Assumed to be fully
funded by debt to the extent that the Company has Net Debt
outstanding. Construction Capital debt financing excludes interest
paid and capitalized.
|
Net Debt
The following table reconciles Net Debt to amounts reported
under IFRS in the Company's Consolidated Interim Financial
Statements as at September 30, as
indicated below. The Company calculates Net Debt as cash and cash
equivalents, less long-term debt and bank indebtedness. Management
believes this measure is useful in assessing the amount of
financial leverage employed.
($
thousands)
|
As at September
30,
|
(Unaudited)
|
|
2021
|
|
2020
|
Cash and cash
equivalents
|
$
|
73,468
|
$
|
178,190
|
Current portion of
long-term debt
|
$
|
(5,279)
|
$
|
(937)
|
Long-term
debt
|
(1,157,736)
|
(712,147)
|
Total
debt
|
$
|
(1,163,015)
|
$
|
(713,084)
|
Net
Debt
|
$
|
(1,089,547)
|
$
|
(534,894)
|
Free Cash Flow
Free Cash Flow, a non-IFRS measure, is used by Management to
evaluate cash flow after investing in the maintenance or expansion
of the Company's asset base. It is defined as cash provided by
operations, less cash additions to long-term assets and capitalized
interest. The following table calculates Free Cash Flow for the
periods indicated below:
($
thousands)
(Unaudited)
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
|
2021
|
2020
|
2021
|
2020
|
Cash provided by
operating activities
|
|
$
|
136,764
|
$
|
135,202
|
$
|
136,501
|
$
|
236,544
|
Additions to long-term
assets
|
|
(136,346)
|
(75,167)
|
(458,586)
|
(253,085)
|
Interest paid and
capitalized(i)
|
|
(5,916)
|
(2,235)
|
(14,525)
|
(5,246)
|
Free Cash
Flow
|
|
$
|
(5,498)
|
$
|
57,800
|
$
|
(336,610)
|
$
|
(21,787)
|
|
|
(i)
|
Certain comparatives
figures have been restated to conform with current year
presentations.
|
Return on Net Assets
Return on Net Assets ("RONA") is calculated by dividing tax
effected earnings from operations (adjusted for items which are not
considered representative of the underlying operations of the
business) by average monthly net assets. Net assets are defined as
total assets (excluding cash and deferred tax assets) less
non-interest bearing liabilities (excluding deferred tax
liabilities). Management believes that RONA is an appropriate basis
upon which to evaluate long-term financial performance.
Forward-Looking Statements
This document contains, and the Company's oral and written
public communications often contain, "forward-looking information"
within the meaning of applicable securities law. These statements
are based on current expectations, estimates, projections, beliefs,
judgments and assumptions based on information available at the
time the applicable forward-looking statement was made and in light
of the Company's experience combined with its perception of
historical trends. Such statements include, but are not limited to,
statements with respect to objectives and goals, in addition to
statements with respect to beliefs, plans, targets, goals,
objectives, expectations, anticipations, estimates, and intentions.
Forward-looking statements are typically identified by words such
as "anticipate", "continue", "estimate", "expect", "may", "will",
"project", "should", "could", "would", "believe", "plan", "intend",
"design", "target", "undertake", "view", "indicate", "maintain",
"explore", "entail", "schedule", "objective", "strategy", "likely",
"potential", "outlook", "aim", "propose", "goal", and similar
expressions suggesting future events or future performance. These
statements are not guarantees of future performance and involve
assumptions, risks and uncertainties that are difficult to
predict.
By their nature, forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or events to differ materially from those
anticipated in such forward-looking statements. The Company
believes the expectations reflected in the forward-looking
statements are reasonable, but no assurance can be given that these
expectations will prove to be correct and such forward-looking
statements should not be unduly relied upon.
Specific forward-looking information in this document may
include, but is not limited to, statements with respect to:
- implications of COVID-19, including implications for supply
chain, workforce availability and consumption patterns;
- future performance, including future financial objectives,
goals and targets, expected capital spend and expected SG&A
expenditures for the Company and each of its operating
segments;
- the execution of the Company's business strategy, including the
development and expected timing of business initiatives, brand
expansion and repositioning, and other growth opportunities, as
well as the impact thereof;
- the impact of international trade conditions on the Company's
business, including access to markets, implications associated with
the spread of foreign animal disease (such as African Swine Fever
("ASF")), and other social, economic and political factors that
affect trade;
- competitive conditions and the Company's ability to position
itself competitively in the markets in which it competes;
- capital projects, including planning, construction, estimated
expenditures, schedules, approvals, expected capacity, in-service
dates and anticipated benefits of construction of new facilities
and expansions of existing facilities;
- the Company's dividend policy, including future levels and
sustainability of cash dividends, the tax treatment thereof and
future dividend payment dates;
- the impact of commodity prices on the Company's operations and
financial performance, including the use and effectiveness of
hedging instruments;
- expected future cash flows and the sufficiency thereof, sources
of capital at attractive rates, future contractual obligations,
future financing options, renewal of credit facilities, and
availability of capital to fund growth plans, operating obligations
and dividends;
- operating risks, including the execution, monitoring and
continuous improvement of the Company's food safety programs,
animal health initiatives and cost reduction initiatives;
- the implementation, cost and impact of environmental
sustainability initiatives, as well as the anticipated future cost
of remediating environmental liabilities;
- the adoption of new accounting standards and the impact of such
adoption on the financial position of the Company;
- expectations regarding pension plan performance, including
future pension plan assets, liabilities and contributions; and
- developments and implications of actual or potential legal
actions.
Various factors or assumptions are typically applied by the
Company in drawing conclusions or making the forecasts,
projections, predictions or estimations set out in the
forward-looking statements. These factors and assumptions are based
on information currently available to the Company, including
information obtained by the Company from third-party sources and
include but are not limited to the following:
- expectations regarding the impact and future implications of
COVID-19 and adaptations in operations, customer and consumer
behaviour, economic patterns and international trade;
- the competitive environment, associated market conditions and
market share metrics, category growth or contraction, the
expected behaviour of competitors and customers and trends in
consumer preferences;
- the success of the Company's business strategy, including
execution of the strategy in each of the Meat Protein and Plant
Protein Groups;
- prevailing commodity prices, interest rates, tax rates and
exchange rates;
- the economic condition of and the socio-political dynamics
between Canada, the U.S.,
Japan and China, and the ability of the Company to
access markets in these countries;
- the spread of foreign animal disease (including ASF),
preparedness strategies to manage such spread, and implications for
all protein markets;
- the availability of capital to fund future capital requirements
associated with existing operations, assets and projects;
- expectations regarding participation in and funding of the
Company's pension plans;
- the availability of insurance coverage to manage certain
liability exposures;
- the extent of future liabilities and recoveries related to
legal claims;
- prevailing regulatory, tax and environmental laws; and
- future operating costs and performance, including the Company's
ability to achieve operating efficiencies and maintain high sales
volumes, high turnover of inventories and high turnover of accounts
receivable.
Readers are cautioned that these assumptions may prove to be
incorrect in whole or in part. The Company's actual results may
differ materially from those anticipated in any forward-looking
statements.
Factors that could cause actual results or outcomes to differ
materially from the results expressed, implied, or projected in the
forward-looking statements contained in this document include,
among other things, risks associated with the following:
- implications of COVID-19 on the operations and financial
performance of the Company, as well the implications for macro
socio-economic trends;
- competition, market conditions and the activities of
competitors and customers, including the expansion or contraction
of key categories (including plant protein);
- the health status of livestock, including the impact of
potential pandemics;
- international trade and access to markets, as well as social,
political and economic dynamics affecting same;
- availability of and access to capital;
- decision respecting the return of capital to shareholders;
- the execution of capital projects, including cost, schedule and
regulatory variables;
- food safety, consumer liability and product recalls;
- cyber security and the maintenance and operation of the
Company's information systems and processes;
- acquisitions and divestitures;
- climate change;
- fluctuations in the debt and equity markets;
- fluctuations in interest rates and currency exchange rates;
- pension assets and liabilities;
- cyclical nature of the cost and supply of hogs and the
competitive nature of the pork market generally;
- the effectiveness of commodity and interest rate hedging
strategies;
- impact of changes in the market value of the biological assets
and hedging instruments;
- the supply management system for poultry in Canada;
- availability of plant protein ingredients;
- intellectual property, including product innovation, product
development, brand strategy and trademark protection;
- consolidation of operations and focus on protein;
- the use of contract manufacturers;
- reputation;
- weather;
- compliance with government regulation and adapting to changes
in laws;
- actual and threatened legal claims;
- consumer trends and changes in consumer tastes and buying
patterns;
- environmental regulation and potential environmental
liabilities;
- consolidation in the retail environment;
- employment matters, including complying with employment laws
across multiple jurisdictions, the potential for work stoppages due
to non-renewal of collective agreements, recruiting and retaining
qualified personnel, reliance on key personnel and succession
planning;
- pricing of products;
- managing the Company's supply chain;
- changes in International Financial Reporting Standards and
other accounting standards that the Company is required to adhere
to for regulatory purposes; and
- other factors as set out under the heading "Risk Factors" in
the Company's Management Discussion and Analysis for the year ended
December 31, 2020.
The Company cautions readers that the foregoing list of factors
is not exhaustive.
Readers are further cautioned that some of the forward-looking
information, such as statements concerning future capital
expenditures, Adjusted EBITDA Margin growth in the Meat Protein
Group, expected sales and growth margin targets in the Plant
Protein Group and SG&A spend, may be considered to be financial
outlooks for purposes of applicable securities legislation. These
financial outlooks are presented to evaluate potential future
earnings and anticipated future uses of cash flows and may not be
appropriate for other purposes. Readers should not assume these
financial outlooks will be achieved.
More information about risk factors can be found under the
heading "Risk Factors" in the Company's Annual Management's
Discussion and Analysis for the year ended December 31, 2020, that is available on SEDAR at
www.sedar.com. The reader should review such section in detail.
Additional information concerning the Company, including the
Company's Annual Information Form, is available on SEDAR at
www.sedar.com.
All forward-looking statements included herein speak only as of
the date hereof. Unless required by law, the Company does not
undertake any obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. All forward-looking statements
contained herein are expressly qualified by this cautionary
statement.
About Maple Leaf Foods Inc.
Maple Leaf Foods is a carbon neutral company with a vision to be
the most sustainable protein company on earth, responsibly
producing food products under leading brands including Maple Leaf®,
Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®,
Schneiders® Country Naturals®, Mina®, Greenfield Natural Meat Co.®,
Lightlife® and Field Roast™. The Company employs approximately
13,500 people and does business primarily in Canada, the U.S. and Asia. The Company is headquartered in
Mississauga, Ontario and its
shares trade on the Toronto Stock Exchange (MFI).
Consolidated Interim Balance Sheets
(In thousands of
Canadian dollars)
(Unaudited)
|
As at September
30,
2021
|
As at September 30,
2020
|
As at December 31,
2020
|
ASSETS
|
|
|
(Audited)
|
Current
assets
|
|
|
|
|
Cash and cash
equivalents
|
$
|
73,468
|
$
|
178,190
|
$
|
100,828
|
Accounts
receivable
|
200,544
|
136,827
|
159,750
|
Notes
receivable
|
69,455
|
32,107
|
31,550
|
Inventories
|
432,502
|
401,339
|
398,070
|
Biological
assets
|
131,257
|
121,828
|
125,648
|
Income taxes
recoverable
|
1,830
|
—
|
1,830
|
Prepaid expenses and
other assets
|
34,373
|
50,156
|
64,517
|
Assets held for
sale
|
—
|
734
|
575
|
|
$
|
943,429
|
$
|
921,181
|
$
|
882,768
|
Property and
equipment
|
2,110,055
|
1,576,653
|
1,721,487
|
Right-of-use
assets
|
173,879
|
230,771
|
222,705
|
Investments
|
22,731
|
16,398
|
15,910
|
Other long-term
assets
|
9,304
|
10,121
|
9,568
|
Deferred tax
asset
|
31,822
|
5,900
|
14,070
|
Goodwill
|
651,295
|
661,599
|
652,501
|
Intangible
assets
|
374,066
|
351,587
|
341,196
|
Total assets
|
$
|
4,316,581
|
$
|
3,774,210
|
$
|
3,860,205
|
LIABILITIES AND
EQUITY
|
|
|
|
|
Current
liabilities
|
|
|
|
|
Accounts payable and
accruals
|
$
|
531,703
|
$
|
468,113
|
$
|
501,529
|
Current portion of
provisions
|
773
|
2,710
|
1,529
|
Current portion of
long-term debt
|
5,279
|
937
|
900
|
Current portion of
lease obligations
|
38,664
|
41,797
|
79,601
|
Income taxes
payable
|
31,592
|
3,482
|
27,639
|
Other current
liabilities
|
56,966
|
35,572
|
55,849
|
|
$
|
664,977
|
$
|
552,611
|
$
|
667,047
|
Long-term
debt
|
1,157,736
|
712,147
|
745,048
|
Lease
obligations
|
149,475
|
207,072
|
160,636
|
Employee
benefits
|
91,063
|
183,563
|
188,946
|
Provisions
|
44,504
|
43,773
|
44,230
|
Other long-term
liabilities
|
4,742
|
18,303
|
11,918
|
Deferred tax
liability
|
137,030
|
117,622
|
109,916
|
Total
liabilities
|
$
|
2,249,527
|
$
|
1,835,091
|
$
|
1,927,741
|
|
|
|
|
|
Shareholders'
equity
|
|
|
|
|
Share
capital
|
$
|
847,013
|
$
|
845,986
|
$
|
838,969
|
Retained
earnings
|
1,234,975
|
1,121,233
|
1,124,973
|
Contributed
surplus
|
11,694
|
8,708
|
5,866
|
Accumulated other
comprehensive loss
|
(7,890)
|
(12,878)
|
(13,414)
|
Treasury
stock
|
(18,738)
|
(23,930)
|
(23,930)
|
Total shareholders'
equity
|
$
|
2,067,054
|
$
|
1,939,119
|
$
|
1,932,464
|
Total liabilities and
equity
|
$
|
4,316,581
|
$
|
3,774,210
|
$
|
3,860,205
|
Consolidated Interim Statements of Net Earnings
(In thousands of
Canadian dollars, except share amounts)
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
(Unaudited)
|
|
2021
|
2020
|
2021
|
2020
|
|
|
|
|
|
|
Sales
|
|
$
|
1,188,643
|
$
|
1,057,169
|
$
|
3,400,587
|
$
|
3,174,510
|
Cost of goods
sold
|
|
1,000,485
|
829,055
|
2,883,819
|
2,651,723
|
Gross profit
|
|
$
|
188,158
|
$
|
228,114
|
$
|
516,768
|
$
|
522,787
|
Selling, general and
administrative expenses
|
|
120,263
|
127,165
|
347,067
|
363,899
|
Earnings before the
following:
|
|
$
|
67,895
|
$
|
100,949
|
$
|
169,701
|
$
|
158,888
|
Restructuring and other
related costs
|
|
840
|
1,732
|
3,698
|
3,070
|
Other (income)
expense
|
|
(965)
|
1,378
|
7,194
|
7,866
|
Earnings before
interest and income taxes
|
|
$
|
68,020
|
$
|
97,839
|
$
|
158,809
|
$
|
147,952
|
Interest expense and
other financing costs
|
|
5,683
|
7,474
|
16,362
|
23,434
|
Earnings before income
taxes
|
|
$
|
62,337
|
$
|
90,365
|
$
|
142,447
|
$
|
124,518
|
Income tax
expense
|
|
17,858
|
24,389
|
41,502
|
36,595
|
Net earnings
|
|
$
|
44,479
|
$
|
65,976
|
$
|
100,945
|
$
|
87,923
|
|
|
|
|
|
|
Earnings per share
attributable to common
shareholders:
|
|
|
|
|
|
Basic earnings per
share
|
|
$
|
0.36
|
$
|
0.54
|
$
|
0.82
|
$
|
0.72
|
Diluted earnings per
share
|
|
$
|
0.35
|
$
|
0.53
|
$
|
0.80
|
$
|
0.71
|
Weighted average number
of shares (millions):
|
|
|
|
|
|
Basic
|
|
123.5
|
123.2
|
123.4
|
123.2
|
Diluted
|
|
125.5
|
124.6
|
125.7
|
124.3
|
Consolidated Interim Statements of Other
Comprehensive
Income (Loss)
(In thousands of
Canadian dollars)
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
(Unaudited)
|
2021
|
2020
|
2021
|
2020
|
|
|
|
|
|
Net earnings
|
$
|
44,479
|
$
|
65,976
|
$
|
100,945
|
$
|
87,923
|
Other comprehensive
income (loss)
|
|
|
|
|
Actuarial gains
(losses) that will not be reclassified to
profit or loss (Net of tax of $0.9 million
and $25.8 million; 2020:
$0.2 million and $15.4 million)
|
$
|
2,556
|
$
|
(677)
|
$
|
75,717
|
$
|
(44,963)
|
Items that are or may
be reclassified subsequently
to
profit or loss:
|
|
|
|
|
Change in fair value of
investments (Net of tax of
$1.0 million and $1.0 million; 2020: $0.0 million and
$0.0 million)
|
$
|
2,945
|
$
|
—
|
$
|
2,945
|
$
|
—
|
Change in accumulated
foreign currency translation
adjustment (Net of tax of $0.0 million and
$0.0 million; 2020: $0.0
million and $0.0 million)
|
6,267
|
(4,885)
|
(3,883)
|
8,652
|
Change in foreign
exchange on long-term debt
designated as a net investment hedge (Net of
tax of $1.1 million and $0.4 million;
2020: $0.8 million and $1.2
million)
|
(5,456)
|
4,413
|
1,826
|
(6,887)
|
Change in cash flow
hedges (Net of tax of $0.7
million and $1.7 million; 2020: $0.5 million and
$6.1 million)
|
(2,157)
|
1,383
|
4,636
|
(17,436)
|
Total items that are or
may be reclassified
subsequently to profit or loss
|
$
|
1,599
|
$
|
911
|
$
|
5,524
|
$
|
(15,671)
|
Total other
comprehensive income (loss)
|
$
|
4,155
|
$
|
234
|
$
|
81,241
|
$
|
(60,634)
|
Comprehensive
income
|
$
|
48,634
|
$
|
66,210
|
$
|
182,186
|
$
|
27,289
|
Consolidated Interim Statements of Changes in Total
Equity
|
|
|
|
Accumulated other
comprehensive
income (loss)(i)
|
|
|
(In thousands of Canadian dollars)
(Unaudited)
|
Share
capital
|
Retained
earnings
|
Contributed
surplus
|
Foreign currency
translation adjustment
|
Unrealized gains and
losses on cash flow hedges
|
Unrealized gains on
fair value of investments
|
Treasury
stock
|
Total
equity
|
Balance at December
31, 2020
|
$
|
838,969
|
1,124,973
|
5,866
|
3,002
|
(16,416)
|
—
|
(23,930)
|
$
|
1,932,464
|
Net earnings
|
—
|
100,945
|
—
|
—
|
—
|
—
|
—
|
100,945
|
Other
comprehensive income (loss)(ii)
|
—
|
75,717
|
—
|
(2,057)
|
4,636
|
2,945
|
—
|
81,241
|
Dividends declared
($0.54 per share)
|
—
|
(66,660)
|
—
|
—
|
—
|
—
|
—
|
(66,660)
|
Share-based
compensation expense
|
—
|
—
|
17,738
|
—
|
—
|
—
|
—
|
17,738
|
Deferred taxes on
share-based compensation
|
—
|
—
|
(450)
|
—
|
—
|
—
|
—
|
(450)
|
Exercise of stock
options
|
8,711
|
—
|
—
|
—
|
—
|
—
|
—
|
8,711
|
Settlement of
share-based compensation
|
—
|
—
|
(9,679)
|
—
|
—
|
—
|
5,192
|
(4,487)
|
Change in obligation
for repurchase of
shares
|
(667)
|
—
|
(1,781)
|
—
|
—
|
—
|
—
|
(2,448)
|
Balance at September
30, 2021
|
$
|
847,013
|
1,234,975
|
11,694
|
945
|
(11,780)
|
2,945
|
(18,738)
|
$
|
2,067,054
|
|
|
|
|
|
|
|
|
Accumulated other
comprehensive
income (loss)(i)
|
|
|
(In thousands of Canadian dollars)
(Unaudited)
|
Share
capital
|
Retained
earnings
|
Contributed
surplus
|
Foreign currency
translation adjustment
|
Unrealized gains and
losses on cash flow hedges
|
Unrealized gains on
fair value of investments
|
Treasury
stock
|
Total
equity
|
Balance at December 31,
2019
|
$
|
840,005
|
1,137,450
|
—
|
4,274
|
(1,481)
|
—
|
(30,378)
|
$
|
1,949,870
|
Net earnings
|
—
|
87,923
|
—
|
—
|
—
|
—
|
—
|
87,923
|
Other
comprehensive income (loss)(ii)
|
—
|
(44,963)
|
—
|
1,765
|
(17,436)
|
—
|
—
|
(60,634)
|
Dividends declared
($0.48 per share)
|
—
|
(59,177)
|
—
|
—
|
—
|
—
|
—
|
(59,177)
|
Share-based
compensation expense
|
—
|
—
|
12,161
|
—
|
—
|
—
|
—
|
12,161
|
Deferred taxes on
share-based compensation
|
—
|
—
|
400
|
—
|
—
|
—
|
—
|
400
|
Exercise of stock
options
|
1,012
|
—
|
—
|
—
|
—
|
—
|
—
|
1,012
|
Settlement of
share-based compensation
|
—
|
—
|
(9,738)
|
—
|
—
|
—
|
6,448
|
(3,290)
|
Change in obligation
for repurchase of
shares
|
4,969
|
—
|
5,885
|
—
|
—
|
—
|
—
|
10,854
|
Balance at September
30, 2020
|
$
|
845,986
|
1,121,233
|
8,708
|
6,039
|
(18,917)
|
—
|
(23,930)
|
$
|
1,939,119
|
|
|
(i)
|
Items that are or
may be subsequently reclassified to profit or
loss.
|
(ii)
|
Included in other
comprehensive income (loss) is the change in actuarial gains and
losses that will not be reclassified to profit or loss and has been
reclassified to retained earnings.
|
Consolidated Interim Statements of Cash Flows
(In thousands of
Canadian dollars)
|
|
Three months ended
September 30,
|
Nine months ended
September 30,
|
(Unaudited)
|
|
2021
|
|
2020(i)
|
|
2021
|
|
2020(i)
|
CASH PROVIDED BY (USED
IN):
|
|
|
|
|
|
|
|
|
Operating
activities
|
|
|
|
|
Net earnings
|
$
|
44,479
|
$
|
65,976
|
$
|
100,945
|
$
|
87,923
|
Add (deduct) items not
affecting cash:
|
|
|
|
|
Change in fair value of
biological assets
|
(6,630)
|
(40,176)
|
6,779
|
1,159
|
Depreciation and
amortization
|
47,800
|
48,699
|
148,201
|
145,242
|
Share-based
compensation
|
8,509
|
4,320
|
17,738
|
12,161
|
Deferred income
taxes
|
(7,824)
|
19,432
|
(17,694)
|
12,535
|
Income tax
current
|
25,682
|
4,957
|
59,196
|
24,060
|
Interest expense and
other financing costs
|
5,683
|
7,474
|
16,362
|
23,434
|
Loss (gain) on sale of
long-term assets
|
1,226
|
(2,724)
|
1,919
|
(2,158)
|
Asset
impairment
|
—
|
(18)
|
436
|
1,554
|
Change in fair value of
non-designated derivatives
|
6,042
|
(23,693)
|
(2,375)
|
(11,027)
|
Change in net pension
obligation
|
3,620
|
2,059
|
3,594
|
6,478
|
Net income taxes
paid
|
(10,545)
|
(12,807)
|
(57,248)
|
(21,151)
|
Interest paid, net of
capitalized interest
|
(5,373)
|
(8,536)
|
(16,766)
|
(23,108)
|
Change in provision for
restructuring and other related costs
|
(156)
|
(90)
|
(224)
|
(2,776)
|
Change in derivatives
margin
|
4,888
|
19,194
|
4,492
|
7,400
|
Other
|
(4,631)
|
3,386
|
(5,989)
|
4,905
|
Change in non-cash
operating working capital
|
23,994
|
47,749
|
(122,865)
|
(30,087)
|
Cash provided by
operating activities
|
$
|
136,764
|
$
|
135,202
|
$
|
136,501
|
$
|
236,544
|
Investing
activities
|
|
|
|
|
Additions to long-term
assets
|
$
|
(136,346)
|
$
|
(75,167)
|
$
|
(458,586)
|
$
|
(253,085)
|
Interest paid and
capitalized
|
(5,916)
|
(2,235)
|
(14,525)
|
(5,246)
|
Acquisition of
business
|
(1,777)
|
—
|
(41,928)
|
—
|
Proceeds from sale of
long-term assets
|
—
|
36,846
|
768
|
36,854
|
Purchase of
investments
|
(3,184)
|
(100)
|
(3,184)
|
(14,053)
|
Proceeds from legal
settlement
|
20,822
|
—
|
20,822
|
—
|
Cash used in investing
activities
|
$
|
(126,401)
|
$
|
(40,656)
|
$
|
(496,633)
|
$
|
(235,530)
|
Financing
activities
|
|
|
|
|
|
|
Dividends
paid
|
$
|
(22,285)
|
$
|
(19,871)
|
$
|
(66,660)
|
$
|
(59,177)
|
Net increase in
long-term debt
|
29,333
|
1,018
|
419,055
|
165,740
|
Payment of lease
obligation
|
(9,125)
|
(8,971)
|
(27,806)
|
(27,085)
|
Exercise of stock
options
|
6,782
|
239
|
8,711
|
1,012
|
Payment of financing
fees
|
(478)
|
—
|
(528)
|
(599)
|
Cash provided by (used
in) financing activities
|
$
|
4,227
|
$
|
(27,585)
|
$
|
332,772
|
$
|
79,891
|
Increase (decrease)
in cash and cash equivalents
|
$
|
14,590
|
$
|
66,961
|
$
|
(27,360)
|
$
|
80,905
|
Cash and cash
equivalents, beginning of period
|
58,878
|
111,229
|
100,828
|
97,285
|
Cash and cash
equivalents, end of period
|
$
|
73,468
|
$
|
178,190
|
$
|
73,468
|
$
|
178,190
|
|
|
(i)
|
Certain comparative
figures have been restated to conform with current year
presentation.
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/maple-leaf-foods-reports-third-quarter-2021-financial-results-301416276.html
SOURCE Maple Leaf Foods Inc.